Spero Therapeutics (SPRO) Cash & Equivalents (2016 - 2026)

Spero Therapeutics (SPRO) has 11 years of Cash & Equivalents data on file, last reported at $56.1 million in Q1 2026.

• Quarterly Cash & Equivalents rose 14.81% year-over-year to $56.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56.1 million (up 14.81% YoY) and the FY2025 annual result came in at $40.3 million, down 23.87% from the prior year.
• Cash & Equivalents improved to $56.1 million in Q1 2026, from $40.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $109.1 million in Q4 2022 to a low of $31.2 million in Q2 2025.
• A 5-year average of $66.0 million and a median of $63.5 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents plunged 55.3% — and 2023, when it jumped 85.99%.
• Tracing SPRO's Cash & Equivalents over 5 years: stood at $109.1 million in 2022, then slumped by 30.04% to $76.3 million in 2023, then slumped by 30.71% to $52.9 million in 2024, then declined by 23.87% to $40.3 million in 2025, then surged by 39.4% to $56.1 million in 2026.
• The last three Cash & Equivalents figures came in at $56.1 million (Q1 2026), $40.3 million (Q4 2025), and $48.6 million (Q3 2025), per Business Quant data.